8-K filing — BIO-TECHNE Corp (TECH)
Filed: 2026-09-14 AccNo: 0001140361-26-036499 Size: 204 KB Item 8.01: Other Events
Stocks · News reference
Bio-Techne Q4 Adj. EPS $0.52, Inline, Sales $321.191M Beat $314.679M Estimate
Bio-Techne (NASDAQ:TECH) reported quarterly earnings of $0.52 per share which met the analyst consensus estimate. This is a 1.89 percent decrease over earnings of $0.53 per share from the same period last year. The
Reference Details
Connected Markets
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
- Source
- benzinga
- Observed
- Checked
- Cadence
- Captured once, then retained as an archive reference
- Status
- fresh
Keep reading
Related Headlines
Why Is Techne (TECH) Down 0.1% Since Last Earnings Report?
Bio-Techne (TECH) reported Q4 adjusted EPS of 52 cents, meeting consensus estimates but declining 1.9% year-over-year. Full-year adjusted EPS of $1.93 increased 0.5% and surpassed consensus by 1%. Q4 revenues of $321.2 million exceeded estimates by 1.26%, though organic growth was modest at 3%. The company improved its balance sheet with cash increasing to $264.7 million and debt declining to $200 million. However, analysts have issued no estimate revisions in the past two months, and the stock carries a Zacks Rank #3 (Hold) with weak growth and momentum scores.
$HAREHOLDER ALERT: The M&A Class Action Firm Continues to Investigate the Merger – AUUD, TECH, CZR and CBAN
Monteverde & Associates PC is investigating four major merger and acquisition deals to determine if they are fair to shareholders: Auddia's merger with McCarthy Finney (1:1 stock exchange), Bio-Techne's sale to Merck KGaA ($73/share), Caesars Entertainment's sale to Fertitta Gaming ($31/share plus ticking consideration), and Colony Bankcorp's merger with First Reliance Bancshares ($19.75 cash or 0.94 stock exchange).
Global Multiplex Assays Market 2026 Edition - Consumables Dominate Multiplex Assays with 68% Market Share
The global multiplex assays market is projected to grow from US$6.8 billion in 2025 to US$12.4 billion by 2030, at a 12.8% CAGR. North America leads with 34% market share, while Asia Pacific is the fastest-growing region at 15.5% CAGR. Consumables dominate with 68% market share, and protein multiplex assays hold 42%. Growth is driven by precision medicine, companion diagnostics, and laboratory automation.